FibroBiologics, Inc. (FBLG)
NASDAQ:FBLG
Want to see FBLG full AI Analyst Report?
Top Page
FibroBiologics, Inc.
(NASDAQ:FBLG)
Select Model
Select Model
Rating:42Neutral
Price Target:
$1.50
▼(-1.96% Downside)
Action:ReiteratedDate:05/01/26
The score is held down primarily by weak financial performance (no revenue, widening losses, heavy cash burn) and a strongly bearish technical setup (deeply below key moving averages with negative MACD). Corporate events provide some offset via regained Nasdaq compliance and cost-saving actions, but monitoring/delisting risk and capital structure actions remain notable. Valuation is constrained by a negative P/E and no dividend support.
Positive Factors
Clinical advancement and cGMP manufacturing
FibroBiologics progressed its fibroblast platform into a Phase 1/2 study and completed cGMP manufacturing of the first drug batch. Clinical initiation plus on‑site GMP capability materially reduce translational and operational risk and support sustained development execution over coming months.
Negative Factors
No revenue and widening losses
FibroBiologics remains pre‑commercial with no reported revenue and net losses widening to roughly $18.7M TTM. Persistent unprofitability limits internal funding capacity, increases dependence on external capital, and elevates execution and dilution risk unless clinical data change the financial profile.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical advancement and cGMP manufacturing
FibroBiologics progressed its fibroblast platform into a Phase 1/2 study and completed cGMP manufacturing of the first drug batch. Clinical initiation plus on‑site GMP capability materially reduce translational and operational risk and support sustained development execution over coming months.
Read all positive factors
FibroBiologics, Inc. (FBLG) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.13M
Dividend YieldN/A
Average Volume (3M)978.93K
Price to Earnings (P/E)―
Beta (1Y)0.41
Revenue GrowthN/A
EPS Growth-30.18%
CountryUS
Employees13
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.00
Shares Outstanding3,512,845
10 Day Avg. Volume1,423,641
30 Day Avg. Volume978,931
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.63
Price to Sales (P/S)0.00
P/FCF Ratio-0.60
Enterprise Value/Market Cap0.05
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.56
Enterprise Value/Ebitda-0.01
Forecast
1Y Price Target
$19.00Price Target Upside1141.83% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-4.21
Revenue Forecast (FY)N/A
FibroBiologics, Inc. Business Overview & Revenue Model
Company Description
FibroBiologics, Inc., a clinical-stage cell therapy company, develops and commercializes fibroblast-based therapies in the United States. It is developing CybroCell, for the treatment of degenerative disc disease; CYMS101 to treat multiple scleros...
How the Company Makes Money
null...
FibroBiologics, Inc. Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
38
Negative
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -465.00K | -832.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -17.87M | -17.61M | -10.57M | -15.90M | -4.37M | -1.58M |
| Net Income | -18.68M | -18.65M | -11.16M | -16.48M | -5.12M | -1.58M |
Balance Sheet | ||||||
| Total Assets | 5.94M | 9.62M | 16.45M | 11.82M | 4.82M | 468.00K |
| Cash, Cash Equivalents and Short-Term Investments | 1.48M | 4.89M | 13.98M | 9.16M | 2.27M | 407.00K |
| Total Debt | 2.23M | 2.41M | 10.55M | 1.75M | 7.52M | 1.30M |
| Total Liabilities | 3.34M | 3.46M | 13.71M | 10.57M | 8.82M | 1.76M |
| Stockholders Equity | 2.60M | 6.16M | 2.73M | 1.25M | -4.00M | -1.29M |
Cash Flow | ||||||
| Free Cash Flow | -15.70M | -16.66M | -12.09M | -6.90M | -4.07M | -1.41M |
| Operating Cash Flow | -15.48M | -16.39M | -11.90M | -6.40M | -4.07M | -1.41M |
| Investing Cash Flow | -219.00K | -262.00K | -184.00K | -495.00K | 0.00 | 0.00 |
| Financing Cash Flow | 8.52M | 7.57M | 16.91M | 13.79M | 5.92M | 1.82M |
FibroBiologics, Inc. Technical Analysis
Negative
1.53
Price Trends
4.61
Negative
5.27
Negative
7.93
Negative
Market Momentum
-1.09
Negative
25.35
Positive
68.18
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FBLG, the sentiment is Negative. The current price of 1.53 is below the 20-day moving average (MA) of 2.47, below the 50-day MA of 4.61, and below the 200-day MA of 7.93, indicating a bearish trend. The MACD of -1.09 indicates Negative momentum. The RSI at 25.35 is Positive, neither overbought nor oversold. The STOCH value of 68.18 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FBLG.
FibroBiologics, Inc. Risk Analysis
FibroBiologics, Inc. disclosed 82 risk factors in its most recent earnings report. FibroBiologics, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
FibroBiologics, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $12.42M | -9.61 | -22.03% | ― | -95.92% | 96.05% | |
47 Neutral | $6.78M | -0.28 | -257.81% | ― | ― | 82.64% | |
43 Neutral | $23.67M | -17.14 | 354.21% | ― | -13.43% | 83.03% | |
42 Neutral | $5.13M | -0.25 | -1292.87% | ― | ― | -30.18% | |
40 Underperform | $7.08M | -13.72 | -27.54% | ― | -100.00% | 97.01% |
* Healthcare Sector Average
FBLG
FibroBiologics, Inc.
1.46
-17.56
-92.33%
BLRX
Bioline RX Ltd Sponsored ADR
2.86
-0.39
-11.91%
CRIS
Curis
0.59
-1.86
-75.84%
SYBX
Synlogic
0.61
-0.57
-48.29%
LEXX
Lexaria Bioscience
0.71
-0.43
-37.63%
PCSA
Processa Pharmaceuticals
2.55
-3.60
-58.54%
FibroBiologics, Inc. Corporate Events
Delistings and Listing ChangesRegulatory Filings and Compliance
FibroBiologics Secures Nasdaq Listing Compliance, Under Monitoring
Positive
Apr 20, 2026
On April 20, 2026, FibroBiologics announced that Nasdaq confirmed the company has demonstrated compliance with all criteria for continued listing on the Nasdaq Capital Market, including the $2.5 million stockholders’ equity requirement and t...
Business Operations and StrategyRegulatory Filings and ComplianceShareholder Meetings
FibroBiologics Lowers Quorum Requirement in Amended Bylaws
Neutral
Apr 17, 2026
On April 16, 2026, FibroBiologics, Inc.’s board of directors amended and restated the company’s bylaws to lower the quorum requirement for stockholder meetings from a majority of the voting power to one-third of the voting power entitl...
Business Operations and StrategyRegulatory Filings and Compliance
FibroBiologics Ends Texas Sublease, Consolidates Houston Operations
Positive
Apr 9, 2026
On April 3, 2026, FibroBiologics, Inc. disclosed that it had entered into a Sublease Buyout Agreement with United Fire Casualty Co. to terminate a sublease for office space in Webster, Texas, effective April 2, 2026, well ahead of the original No...
Regulatory Filings and ComplianceStock Split
FibroBiologics Implements One-for-Twenty Reverse Stock Split
Neutral
Apr 3, 2026
On March 25, 2026, FibroBiologics, Inc. filed a Certificate of Amendment in Delaware, which took effect on March 30, 2026, to implement a one-for-twenty reverse stock split of its issued and outstanding common shares. The reverse split changed the...
Private Placements and FinancingRegulatory Filings and Compliance
FibroBiologics Announces Public Offering and Warrant Agreements
Neutral
Apr 2, 2026
FibroBiologics, Inc., a clinical-stage biotech developer of fibroblast-based therapies for chronic diseases, priced and launched a best-efforts public offering on March 31, 2026, comprising 1,028,788 common shares, 1,243,940 pre-funded warrants an...
Executive/Board Changes
FibroBiologics Updates CFO Compensation to Support Leadership
Positive
Mar 6, 2026
On March 4, 2026, FibroBiologics, Inc. disclosed that its Compensation Committee approved an increase in the annual base salary for Chief Financial Officer Jason D. Davis to $400,000, effective January 1, 2026. The decision, which keeps Davis̵...
Business Operations and StrategyPrivate Placements and FinancingShareholder MeetingsStock Split
FibroBiologics Shareholders Approve Reverse Split, Warrant Issuances
Positive
Feb 23, 2026
FibroBiologics, Inc. reported that at a special meeting of stockholders held on February 20, 2026, investors approved an amendment to its certificate of incorporation authorizing the board to implement a reverse stock split in a range of 1-for-5 t...
Delistings and Listing ChangesRegulatory Filings and ComplianceShareholder MeetingsStock Split
FibroBiologics Faces Nasdaq Delisting Review After Noncompliance
Negative
Feb 6, 2026
On August 4, 2025, FibroBiologics, Inc. was notified by Nasdaq that its market value of listed securities had fallen below the required $35 million minimum for 30 consecutive trading days, triggering a 180-day grace period through February 2, 2026...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.